Celcuity Inc — Biomedical Watch V2

Traitements5programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Arm A: Gedatolisib + Palbociclib + FulvestrantThis is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Bulgaria, China, Czechia, Denmark, …	À vérifier
Arm B: Ribociclib + FulvestrantThis is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Bulgaria, China, Czechia, Denmark, …	À vérifier
Arm C: Gedatolisib + Palbociclib + LetrozoleThis is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Bulgaria, China, Czechia, Denmark, …	À vérifier
Arm D: Ribociclib + LetrozoleThis is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Bulgaria, China, Czechia, Denmark, …	À vérifier
Arm A: Gedatolisib + Palbociclib + FulvestrantThis is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Bulgaria, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Malaysia, Mexico, Poland, Portugal, Romania, South Korea, …	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Arm A: Gedatolisib + Palbociclib + Fulvestrant	Cancer	Phase 3	NCT06757634	Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.